Press Release

Carl Zeiss Meditec achieves slight revenue growth in first quarter of 2023/24

Decline in profit due to expected weaker product mix

9 February 2024

Jena, Germany | February 9, 2024 | Carl Zeiss Meditec AG

Carl Zeiss Meditec generated revenue of €475.0m in the first quarter of fiscal year 2023/24 (prior year: €470.3m), corresponding to a growth of +1.0% (adjusted for currency effects: +3.3%). Order backlog normalized to around €315m. Earnings before interest and taxes (EBIT) declined to around €43.5m (prior year: €60.3m). The EBIT margin was 9.2% (prior year: 12.8%).

Dr. Markus Weber, President and CEO of Carl Zeiss Meditec AG commented on the Q1 results: “We have made a solid start to the new fiscal year. The planned measures to clear the Chinese distribution channel as well as currency developments have impacted revenue and earnings as anticipated. However, a positive effect resulted from the equipment business, which achieved good deliveries and significantly improved production times.”

Revenue growth primarily boosted by equipment business and SBU Microsurgery

Revenue in the Ophthalmic Devices strategic business unit (SBU) decreased by -2.0% in the first three months of fiscal year 2023/24 (adjusted for currency effects: 0.0%), to €351.1m (prior year: €358.2m). In particular the planned reduction of stocks of consumables for refractive surgery in the Chinese distribution channel had an adverse effect. Currency effects also had a negative impact.

The strategic business unit Microsurgery achieved revenue growth of +10.6% (adjusted for currency effects: +13.7%) to €123.9m (prior year: €112.0m). The SBU continued to benefit from the reduction of the high order backlog.

Heterogeneous sales development in the reporting regions

Revenue in the EMEA1 region increased by +28.2% (adjusted for currency effects: +30.9%) to €156.5m (prior year: €122.1m). The core markets France, Italy and Spain are making positive contributions to growth.

Revenue in the Americas region decreased by -19.9% (adjusted for currency effects: -16.6%) from €139.9m to €112.1m. The positive trend in Latin America continued, while the U.S. experienced a decline at the start of the fiscal year.

The APAC2 region recorded a slight decline in revenue of -0.9% (adjusted for currency effects: +0.4%), to €206.4m (prior fiscal year: €208.2m). India and Southeast Asia are making positive contributions. The Chinese market, meanwhile, showed a decline in revenue due to the planned reduction of stocks of surgical consumables.

Operating result down compared with prior year, as expected

The operating result (earnings before interest and taxes, EBIT) declined in the first quarter of fiscal year 2023/24, to €43.5m (prior year: €60.3m). As expected, gross profit came under considerable pressure due to a less favorable product mix – resulting from a higher proportion of devices and a lower proportion of consumables due to the reduction of stocks in the Chinese distribution channel.

The EBIT margin in the first three months of fiscal year 2023/24 was 9.2% (prior year: 12.8%). Adjusted for special effects, this figure was 9.7% (prior year: 13.4%). Earnings per share benefited from gains on currency hedges and amounted to €0.42 in the first quarter (prior year: €0.57).

Outlook for the further course of business in 2023/24

In spite of geopolitical risks and an increasingly difficult macroeconomic environment, the Company generally expects to see further market growth. Revenue is expected to grow at least in line with the market growth. A gradual recovery of the EBIT margin is expected in the further course of the year. EBIT for fiscal year 2023/24 as a whole is expected to be around the prior year’s level.

  • All figures in €m

    3 months 2023/24

    3 months 2022/23

    Change from prior year

    Change from prior year (currency-adjusted)

    Ophthalmology

    351.1

    358.2

    -2.0%

    0,0%

    Microsurgery

    123.9

    112.0

    +10.6%

    +13.7%

    Consolidated

    475.0

    470.3

    +1.0%

    +3.3%

    Further information on our publication and the Analyst Conference Call on the results for the first three months of fiscal year 2023/24 can be found at https://www.zeiss.de/meditec-ag/investor-relations/finanzkalender/telefonkonferenzen.html

  • All figures in €m

    3 months 2023/24

    3 months 2022/23

    Change from prior year

    Change from prior year (currency-adjusted)

    EMEA

    156.5

    122.1

    +28.2%

    +30.9%

    Americas

    112.1

    139.9

    -19.9%

    -16.6%

    APAC

    206.4

    208.2

    -0.9%

    +0.4%

    Consolidated

    475.0

    470.3

    +1.0%

    +3.3%

    Further information on our publication and the Analyst Conference Call on the results for the first three months of fiscal year 2023/24 can be found at https://www.zeiss.de/meditec-ag/investor-relations/finanzkalender/telefonkonferenzen.html

Press & Investor Relations Contact

Sebastian Frericks

Director Group Finance & Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-116
investors.meditec@zeiss.com

Brief profile

Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 4,823 employees worldwide, the Group generated revenue of €2,089.3m in fiscal year 2022/23 (to 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

For more information visit our website at www.zeiss.com/med

 


Share this page

  • 1

    Europe/Middle East/Africa

  • 2

    Asia/Pacific